Solution Sheet
Process Intelligence for Biologics Finance Operations
Transfer Pricing | Intercompany Reconciliation | Cost-of-Goods-Sold Mapping
CO-DELIVERED WITH WNS (CAPGEMINI)
Process Intelligence (BusinessOptix) + Managed Finance Operations (WNS)
4x Leader: Gartner F&A BPO Magic Quadrant | ISG Procurement BPO Leader | 700+ Global Clients
The Large Molecule Finance Challenge
The antibody-derived biologics market is projected to reach $700–920 billion by the early 2030s. This unprecedented growth is transforming the financial operating models of every pharma and biotech organization with a large molecule portfolio. Unlike small molecule generics, biologics introduce structural complexity into finance operations that conventional ERP configurations and shared service models were never designed to handle.
Why Biologics Break Finance Processes
- Multi-jurisdictional supply chains: IP-holding entities, CDMO manufacturing sites, cold-chain distribution hubs, and specialty pharmacy channels create intercompany transaction volumes that dwarf small molecule operations
- Batch-level cost variability: Bioreactor yield fluctuations, failed batch write-offs, and temperature-excursion events create COGS variances that manual finance processes cannot track at the granularity regulators and investors demand
- Revenue complexity: Government rebate programs (Medicaid, 340B), biosimilar competition pricing, payer-specific contracting, and product returns create Gross-to-Net adjustment requirements that stretch DSO and obscure true revenue recognition
- Regulatory-driven finance: Clinical milestone accounting, IFRS 15 revenue recognition for licensing deals, and Pillar Two minimum tax compliance layer additional reporting demands onto finance teams already operating at capacity
R2R, P2P, and O2C in the Large Molecule Context
The three core finance process pillars—Record to Report, Procure to Pay, and Order to Cash—each carry distinct complexity in large molecule biologics. The table below maps each process to the specific challenges faced by biologics-focused pharma organizations, and illustrates how BusinessOptix and WNS combine to address them.
|
Process |
Large Molecule Complexity |
Finance Pain Point |
BusinessOptix + WNS Value |
|
Record to Report (R2R) |
Multi-entity consolidation across manufacturing, licensing, and distribution arms; batch-level cost allocation; regulatory reserve calculations tied to clinical milestones |
Intercompany reconciliation across 50+ legal entities; COGS variances from yield fluctuations; month-end close exceeds 15 days |
AI-driven process discovery maps R2R as-is state; WNS operates optimised close cycle; BusinessOptix monitors SLA adherence and exception rates in real time |
|
Procure to Pay (P2P) |
Raw material sourcing for biologics (cell culture media, chromatography resins, single-use assemblies); CDMO contract management; cold-chain logistics procurement |
Maverick spend in decentralized R&D labs; 3-way match failures for GMP-grade materials; vendor qualification backlogs delaying AP processing |
End-to-end P2P process mapping with compliance overlays; WNS manages transactional AP and vendor onboarding; BusinessOptix provides process simulation for procurement policy changes |
|
Order to Cash (O2C) |
Specialty pharmacy distribution models; government rebate calculations (Medicaid, 340B); product returns and temperature-excursion credits; biosimilar launch pricing |
Revenue leakage from rebate miscalculations; DSO stretched by payer complexity; manual Gross-to-Net adjustments across product portfolio |
Process intelligence maps O2C variants by channel and geography; WNS delivers managed AR operations; BusinessOptix enables what-if modelling for pricing and channel strategy changes |
Deep Dive: Transfer Pricing, Intercompany Reconciliation & COGS
These three interconnected finance domains represent the highest-friction areas in large molecule finance operations. Each sits at the intersection of finance, manufacturing, and regulatory compliance—and each is where process intelligence delivers the greatest return.
|
Transfer Pricing |
Intercompany Reconciliation |
COGS Process Mapping |
|
Biologics supply chains span IP-holding entities, manufacturing sites (often CDMOs), and distribution hubs across multiple jurisdictions. Transfer pricing models must account for intangible asset contributions (patents, cell-line IP), contract manufacturing margins, and risk allocation under OECD/BEPS guidelines. BusinessOptix maps and simulates transfer pricing process flows, enabling finance teams to model restructuring scenarios before implementation. |
Large molecule companies routinely manage 50-200+ intercompany agreements covering API transfers, fill-finish services, royalty flows, and shared service charges. Reconciliation failures drive material month-end adjustments and audit findings. BusinessOptix provides process-level visibility into intercompany transaction flows, while WNS manages high-volume reconciliation operations against mapped and agreed process standards. |
Cost of Goods Sold in biologics is inherently variable: batch yield deviations, failed batches, raw material price volatility, and cold-chain logistics costs all create COGS variance. BusinessOptix enables finance and manufacturing teams to co-map the end-to-end COGS process from cell culture through fill-finish to distribution, linking cost drivers to process steps and identifying where variance emerges. |
The BusinessOptix + WNS Co-Delivery Model
A Combined Proposition for Pharma CFOs
WNS (now part of Capgemini) is a four-time Leader in the Gartner Magic Quadrant for F&A BPO and a five-time ISG Leader for Procurement BPO, serving 700+ global clients with 64,500+ professionals across 64 delivery centres. WNS delivers managed finance operations across R2R, P2P, and O2C at scale.
BusinessOptix is an Enterprise Process Intelligence and Operating Model Platform that provides the visibility, governance, and simulation capability that managed services engagements require. BusinessOptix maps the as-is process landscape, identifies transformation opportunities, designs the to-be state, and provides continuous operational monitoring post-transition.
How the Partnership Works
The co-delivery model operates across three phases, ensuring that outsourced or transformed finance operations are underpinned by clear process standards, measurable KPIs, and continuous improvement governance.
|
Phase |
BusinessOptix |
WNS (Capgemini) |
|
1. Discover |
AI Discovery Agent captures as-is R2R, P2P, and O2C processes from SME conversations; builds process repository with compliance overlays; identifies transformation hotspots and automation candidates |
Provides domain benchmarks for pharma finance KPIs; validates process maps against best-practice operating models from 700+ client engagements; sizes the managed services opportunity |
|
2. Transform |
Designs to-be processes using simulation; models transfer pricing restructuring scenarios; creates SOP documentation and role-based operating procedures; defines SLA frameworks and exception-handling protocols |
Executes transition and migration of finance operations; implements automation (RPA, AI invoice processing, automated reconciliation); onboards and trains delivery teams against BusinessOptix process standards |
|
3. Operate |
Provides continuous process monitoring dashboards; tracks SLA adherence, exception rates, and cycle times; enables ongoing process improvement through what-if simulation; delivers regulatory change impact analysis |
Delivers day-to-day managed finance operations for R2R close, P2P transactional processing, and O2C collections; operates against agreed process standards with continuous reporting into BusinessOptix platform |
Why Now: The Convergence Moment
Four forces are converging to make pharma finance transformation urgent:
- Patent Cliff Pressure: Major biologics face loss of exclusivity, driving aggressive M&A and licensing activity. 2025 was the third-highest year in biopharma M&A history. Each acquisition adds legal entities, intercompany agreements, and finance process complexity.
- Biosimilar Competition: Biosimilar market entry compresses margins and demands real-time Gross-to-Net visibility. Finance teams must model pricing scenarios and channel economics with speed and confidence.
- OECD Pillar Two & BEPS 2.0: Global minimum tax and transfer pricing regulations demand process transparency that most pharma finance functions cannot deliver with current tooling.
- AI Readiness: Finance leaders know AI will transform F&A operations, but cannot deploy AI meaningfully without first mapping and standardizing the processes it will operate within. BusinessOptix is the prerequisite.
Next Steps
To explore how BusinessOptix and WNS can accelerate your pharma finance transformation, we invite you to schedule a 30-minute discovery call. We will walk through your specific R2R, P2P, and O2C challenges and demonstrate how our AI Discovery Agent can begin capturing your as-is finance processes in the first session.